Pilot study on esketamine response in treatment-resistant depression: impact of pharmacogenetic, clinical, and demographic variables.

Although patients classified as slower metabolizers of CYP2B6, CYP2C9, and CYP3A4 showed numerically greater improvement in MADRS scores, these differences did not reach statistical significance.

also in 111,027 other papers

Although statistical analysis did not reveal a significant association - likely due to the small sample size (N = 5) - patients receiving fluvoxamine showed a trend toward greater clinical improvement ( Figure 5 ).

also in 53,322 other papers